Evaluation Of The Effectiveness Of Antihypertensive Drug Use In Preeclampsia Patients Hospitalised In RSIA Sitti Khadijah 1 Makassar

Authors

  • Friska Adelia S Universitas Megarezky Makassar, Indonesia
  • Jangga Jangga Program Studi S1 Farmasi, Universitas Megarezky Makassar, Indonesia
  • Qonita Kurnia Anjani Program Studi S1 Farmasi, Universitas Megarezky Makassar, Indonesia

DOI:

https://doi.org/10.70410/jfg.v11i2.336

Keywords:

Preeclampsia, antihypertensives, therapeutic effectiveness

Abstract

Preeclampsia is a medical condition that occurs during pregnancy, characterized by high blood pressure and the presence of protein in the urine (proteinuria) after 20 weeks of gestation. This condition poses a risk to pregnant women, fetuses and newborn babies. Mothers with preeclampsia suffer severe morbidity and mortality due to impaired function of organs such as the kidneys and liver, as well as blood clotting problems, which can occur in hypertension in pregnancy. Problems with the placenta and stunted fetal growth are also risks. Therefore, evaluation of the use of antihypertensive drugs is very important. The goal is to ensure that the drugs used are appropriate, effective and safe for pregnant women. This study aims to determine the profile and effectiveness of the use of antihypertensive drugs in inpatient preeclampsia patients at RSIA Sitti Khadijah 1 Makassar. This research uses a non-experimental (observational) descriptive method. The data used is retrospective, namely in the form of secondary data. The data source comes from medical records of inpatients diagnosed with preeclampsia. The research was conducted at RSIA Sitti Khadijah 1 Makassar for the period January 2023 to April 2024. The results of the study showed that the use of antihypertensive drugs in 47 preeclampsia patients, namely nifedipine monotherapy, was 87%, the combination of nifedipine and methyldopa was 9%, the combination of nifedipine and amlodipine was 4%. Most of the antihypertensives used are effective and have achieved the therapy goals of the Queensland Clinical Guideline 2021. Compliance with the use of antihypertensive drugs and doses was achieved at 96%, while 2% were declared inappropriate. As many as 94% were effective in reducing blood pressure according to therapy goals.

Downloads

Download data is not yet available.

References

ACOG. (2020). Clinical Management Guidelines for Obstetrician – Gynecologists. Obstetrics & Gynecology, 133(76), 168–186. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/07/diagnosis-and-management-of-vulvar-skin-disorders
Andriana, D. D., Utami, E. D., & Sholihat, N. K. (2018). Drug Use Evaluation of Antihypertensive in Pre-Eclampsia In-Patients in Dr. Margono Soekarjo General Hospital Purwokerto Period of January 2015-June 2016. Acta Pharmaciae Indonesia Journal, 6(1), 29–39. https://doi.org/10.5281/zenodo.3707186
Azzahra, F. A., & Yulianti, T. (2021). Identifikasi Drug Related Problems (Drps) Kategori Pemilihan Obat Dan Dosis Pada Pasien Preeklampsia Dan Eklampsia Di Instalasi Rawat Inap Rsup Dr. Soeradji Tirtonegoro Klaten Tahun 2018. 37–53.
Dewi, N. K. (2019). Evaluasi Ketepatan Dan Efektivitas Terapi Hipertensi Pada Ibu Hamil Dengan Preeklampsia/ Eklampsia Di RST dr. Soedjono Kota Magelang Januari 2017-Juni 2018. Universitas Muhammadiyah Surakarta.
Husna, N., Melinda, C., Sugita, R. D., & Anggraeni, R. (2023). Studi Faktor Resiko, Pola Pengobatan, dan Luaran Klinis Pasien Preeklampsia di RSUD Sleman Yogyakarta. Jurnal Sains Farmasi & Klinis, 9(sup), 196. https://doi.org/10.25077/jsfk.9.sup.196-201.2022
Karrar, S. A., & Hong, P. L. (2023). Preeclampsia. Nlm.Nih.Gov. https://www.ncbi.nlm.nih.gov/books/NBK570611/#article-27640.s7 %0A%0A
Khansha, L., & Yuniarni, U. (2023). Evaluasi Penatalaksaan Penggunaan Obat Antihipertensi pada Pasien Preeklampsia di Instalasi Rawat Inap. Jurnal Riset Farmasi, 49–56. https://doi.org/10.29313/jrf.v3i1.3119
Kundarto, W., & Faizah, R. N. (2021). Evaluasi Terapi Antihipertensi Pada Pasien Preeklampsia Berat di Instalasi Rawat Inap RSUD Dr. Moewardi Periode Januari - Juni Tahun 2017. JPSCR: Journal of Pharmaceutical Science and Clinical Research, 6(2), 228. https://doi.org/10.20961/jpscr.v6i2.39487
Madania, Abdulkadir, W. S., Djuwarno, E. N., Suryadi, A. M. A., & Sherina, S. (2024). Studi Penatalaksanaan dan Ketepatan Pengobatan Antihipertensi pada Wanita Hamil di RSUD Toto Kabila. Journal Syifa Sciences and Clinical Research, 6(1), 34–45. https://doi.org/10.37311/jsscr.v6i1.23785
Nabila. (2023). Evaluasi Pengobatan Antihipertensi Pada Pasien Preeklampsia Di RS Islam PKU Muhammadiyah Pekajangan. Borneo Akcaya, 9(2).
Ndwiga, C., Odwe, G., Pooja, S., Ogutu, O., Osoti, A., & Warren, C. E. (2020). Clinical presentation and outcomes of preeclampsia and eclampsia at a national hospital, Kenya: A retrospective cohort study. PLoS ONE, 15(6 June), 1–15. https://doi.org/10.1371/journal.pone.0233323
QCG, Guidelines, Queensland, & Clinical. (2021). Maternity and Neonatal Clinical Guideline Hypertension and pregnancy. Queensland Health, No. MN21.13-V9-R26, 1–39.
Rokhmah, N., Zunita, O., & Septiani, A. (2023). Evaluation of the Antihypertensive Drugs in Preeclampsia Patients To Clinical Outcomes At Rsud Sekarwangi on 2021 Period. Medical Sains?: Jurnal Ilmiah Kefarmasian, 8(4), 1537–1546. https://doi.org/10.37874/ms.v8i4.917
WHO. (2023). Maternal mortality. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/maternal-mortality
Yana, A. U., Brata, C., & Irawati, S. (2023). Studi Penggunaan Antihipertensi pada Pasien Preeklampsia Rawat Jalan di Poliklinik RSIA Bantuan 05.08.05 Surabaya. 14(2), 319–326. https://ejurnal.poltekkes-tjk.ac.id/index.php/JK/

Downloads

Published

2024-08-31

How to Cite

Friska Adelia S, Jangga, J., & Kurnia Anjani, Q. . (2024). Evaluation Of The Effectiveness Of Antihypertensive Drug Use In Preeclampsia Patients Hospitalised In RSIA Sitti Khadijah 1 Makassar. JURNAL FARMASI GALENIKA, 11(2), 94–107. https://doi.org/10.70410/jfg.v11i2.336

Issue

Vol. 11 No. 2 (2024): Jurnal Farmasi Galenika Vol 11 No 2

Section

Artikel

Citation Check

License

Authors who publish in Jurnal Farmasi Galenika agree to the following terms:

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. CC BY includes the following elements:

Creative Commons License

BY: credit must be given to the creator.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.